For childhood neuroblastoma, no clear clinical data is available about XIAP expression and clinical outcome, although XIAP-inhibitors significantly affect tumor growth and death resistance of neuroblastoma in vitro and in vivo (40, 41). Here, XIAP is linked to neoplasm.